







Regeneron will use trove of 23andMe genetic data to develop medical advances.
23andMe Is Terrifying but Not for the Reasons the FDA Thinks
This genetic testing company’s real goal is to hoard your personal data

A Major Drug Company Now Has Access to 23andMe’s Genetic Data. Should You Be Concerned?
Should consumers be concerned?

23andMe's Data Sold to Nonprofit Run by Its Co-Founder - 'And I Still Don't Trust It' - Slashdot
"Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March," writes a Washington Post technology columnist. "Now it's back with the same person in charge — and I still don't trust it." As of this week, genetic data from the more...

Hacker leaks millions more 23andMe user records on cybercrime forum | TechCrunch
The same hacker who leaked stolen 23andMe user data two weeks ago published new data that appears to have been stolen from the genetic testing service.

Genomics Needs A Killer App | TechCrunch
Genomics has undergone a major shift in the last year. The drop in price in the past decade from $3B to $1K to sequence a genome is the 10X force likely to cause an inflection point in a number of health-related industries. But despite the price, right now genomics is a niche product in large part used in and promoted by academia.

Genetics firm 23andMe says user data stolen in credential stuffing attack
23andMe has confirmed to BleepingComputer that it is aware of user data from its platform circulating on hacker forums and attributes the leak to a credential-stuffing attack.

Regenerative medicine today is like the internet in 1993 | TechCrunch
Robin Smith is the co-founder CEO of ORIG3N, a regenerative medical company that has crowdsourced blood samples to create the world’s biggest and most

uBiome's Founders Launch A Microbiome Syndicate on AngelList | TechCrunch
Ubiome is an unusual startup. The three-year-old sequences the collected microbes in the human body and sells $89 kits to those curious to understand

Ramez Naam on Twitter / X
There was a site years ago called CureTogether where patients could share information in a structured way on their disease, regimen, and progress, working towards a sort of bottoms-up clinical trial. 23andMe acquired them and it seems to be mostly dead.— Ramez Naam (@ramez) September 14, 2025
How the microbiome will lead a revolution in the consumerization of personalized medicine and diet | TechCrunch
The human microbiome -- meaning all of our microbes’ genes -- will reshape the consumerization of personalized medicine and diet. Following the human genome project, technological advancements have brought us much closer to acute precision in disease diagnosis and treatment. The microbiome has the potential to change the way we diagnose and treat the most critical diseases of our time.

GainForest: Open tools for regenerative intelligence
Explore nature projects around the world, back community-led restoration, and mint Certs; verifiable proof-of-impact records signed on ATProto.

Monsanto Just Got Access to the World’s Most Powerful Gene-Editing Tool
Agriculture company Monsanto has acquired a non-exclusive global licensing agreement from MIT’s Broad Institute and Harvard to use the CRISPR/Cas9

Scientists Argue the US Ban on Human Gene Editing Will Leave It Behind - Slashdot
Alex Pearlman, reporting for Motherboard: As the biotech revolution accelerates globally, the U.S. could be getting left behind on key technological advances: namely, human genetic modification. A Congressional ban on human germline modification has "drawn new lines in the sand" on gene editing legi...

Accelerating life sciences research
Discover how a specialized AI model, GPT-4b micro, helped OpenAI and Retro Bio engineer more effective proteins for stem cell therapy and longevity research.

Curious 23andMe twin results show why you should take DNA testing with a grain of salt | TechCrunch
If you've ever enthusiastically sent your spit off in the mail, you were probably anxious for whatever unexpected insights the current crop of DNA testing

Steve Jurvetson on investing industrial biotech at SynBioBeta SF 2013